Skip to main content

Table 2 Primary and secondary outcomes of the PORTAL trial

From: Robotic versus Open Pancreatoduodenectomy for Pancreatic and Periampullary Tumors (PORTAL): a study protocol for a multicenter phase III non-inferiority randomized controlled trial

Primary outcomes
 Time to functional recovery, n (days)
 Patients with PDAC who start adjuvant chemotherapy at 8 weeks, n (%)
Secondary outcomes
 Estimated blood loss, ml
 Operative time, min
 Length of hospital stay, days
 30-day morbidity, n (%)
  < Clavien-Dindo grade IIIa
  ≥ Clavien-Dindo grade IIIb
 30-day mortality, n (%)
 90-day mortality, n (%)
 30-day readmission, n (%)
 Reoperation, n (%)
 Quality of life assessment
 Perioperative costs, $
  Resection margin status, n (%)
  Harvested lymph nodes, n
  Positive lymph nodes, n
  Recurrence, n (%)
  Recurrence site, n (%)
  Recurrence-free survival, months
  Overall survival, months
  1. OPD open pancreaticoduodenectomy, RPD robotic pancreaticoduodenectomy, PDAC pancreatic adenocarcinoma